OraSure Technologies, Inc. (OSUR)
| Market Cap | 939.72M |
| Revenue (ttm) | 227.06M |
| Net Income (ttm) | 5.31M |
| Shares Out | 71.98M |
| EPS (ttm) | 0.07 |
| PE Ratio | 191.14 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,281,269 |
| Open | 11.50 |
| Previous Close | 11.47 |
| Day's Range | 11.48 - 13.38 |
| 52-Week Range | 8.58 - 17.79 |
| Beta | -0.28 |
| Analysts | Buy |
| Price Target | 13.25 (-1.0%) |
| Est. Earnings Date | Nov 3, 2021 |
About OSUR
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, Diagnostics and Molecular Solutions. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for OSUR stock is "Buy." The 12-month stock price forecast is 13.25, which is a decrease of -0.97% from the latest price.
News
OraSure Technologies Announces Resignation of CFO Roberto Cuca and Succession Plan
Scott Gleason, SVP, Investor Relations and Corporate Communications, Will Serve as Interim CFO Scott Gleason, SVP, Investor Relations and Corporate Communications, Will Serve as Interim CFO
OraSure Stock Is Trading Lower As Q2 Earnings, Outlook Trail Estimates
OraSure Technologies Inc (NASDAQ: OSUR) reported second-quarter revenues almost doubled to $57.6 million, slightly ahead of the consensus of $56.69 million. Excluding COVID-19 revenues, sales were up 12...
OraSure Technologies (OSUR) Reports Q2 Loss, Tops Revenue Estimates
OraSure (OSUR) delivered earnings and revenue surprises of -150.00% and 1.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies: Q2 Earnings Insights
Shares of OraSure Technologies (NASDAQ:OSUR) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 87.50% over the past year to ($0.02), whic...
OraSure Technologies Reports 2Q21 Revenue of $57.6 Million Driven by Strong Rebound in Core Business
Management to Host Analyst/Investor Call and Webcast Today at 5:00 p.m. ET
OraSure Technologies (OSUR) Earnings Expected to Grow: What to Know Ahead of Q2 Release
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OraSure Technologies, Inc. to Hold 2021 Second Quarter Earnings Conference Call Tuesday, August 3, 2021, 5:00 p.m. ET
BETHLEHEM, Pa., July 27, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 second quarter financial results and certain ...
OraSure Technologies to Present at the Raymond James 2021 Human Health and Innovation Conference
BETHLEHEM, Pa., June 17, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, and microbiome laboratory and analyt...
OraSure and the Will Rodgers Liver Health Foundation to Heighten Awareness Around the Importance of Hepatitis C Testing
Over Half of the Almost Three Million Americans with Hepatitis C Are Not Aware of Their Disease Status Over Half of the Almost Three Million Americans with Hepatitis C Are Not Aware of Their Disease Status
OraSure's COVID-19 Rapid Antigen Tests Gets FDA Emergency Approval for OTC, Professional, Prescription Use
OraSure Technologies Inc (NASDAQ: OSUR) has received FDA Emergency Use Authorization (EUA) for its COVID-19 rapid antigen tests, InteliSwab. These tests detect active COVID-19 infection; the agency has ...
OraSure Technologies Receives Three Emergency Use Authorizations for its COVID-19 Rapid Antigen Tests for Non-Prescri...
Branded as InteliSwab™, the easy-to-use diagnostic tests rapidly detect active COVID-19 infection Branded as InteliSwab™, the easy-to-use diagnostic tests rapidly detect active COVID-19 infection
OraSure Technologies to Present at the Jefferies Virtual Healthcare Conference
BETHLEHEM, Pa., May 28, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical ...
OraSure Resubmits EUA Applications for ELISA COVID-19 Antibody Test
OraSure Technologies Inc (NASDAQ: OSUR) has resubmitted two separate Emergency Use Authorization (EUA) applications for its SARS-CoV-2 Antibody ELISA and the oral specimen collection device. ELISA is in...
OraSure Technologies to Hold Virtual Annual Meeting of Stockholders on May 18, 2021
BETHLEHEM, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), announced that its 2021 Annual Meeting of Stockholders will be a completely virtual meeting, conducted as a li...
Insignia and Partners Support CDC Demonstration Project for Uptake of Self-test Kits for HIV
Free At-Home HIV Testing Kits Free At-Home HIV Testing Kits
OraSure Technologies (OSUR) Beats Q1 Earnings and Revenue Estimates
OraSure (OSUR) delivered earnings and revenue surprises of 66.67% and 0.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies, Inc. Announces First Quarter 2021 Financial Results and Provides COVID-19 Update
First Quarter 2021 Net Revenues of $59 Million Increased 85% Over 2020, Driven by $27 Million in Sales of Sample Collection Devices for COVID-19 Molecular Testing
OraSure Technologies to Hold 2021 First Quarter Earnings Conference Call Wednesday, May 5, 2021, 5:00 p.m. ET
BETHLEHEM, Pa., April 30, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 first quarter financial results and certain ...
OraSure Technologies (OSUR) Earnings Expected to Grow: What to Know Ahead of Q1 Release
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OraSure Files Emergency Use Application For COVID-19 Kits For Home Use And Professional Test
OraSure Technologies Inc (NASDAQ: OSUR) has submitted an application to the FDA seeking Emergency Use Authorization (EUA) for its COVID-19 rapid antigen test for both Prescription Home Use and Professio...
OraSure Technologies Submits COVID-19 Rapid Antigen Prescription Home Self-Test and Professional Test to FDA for Emer...
Tests designed to detect active COVID-19 infection with a simple, easy-to-use workflow Tests designed to detect active COVID-19 infection with a simple, easy-to-use workflow
OraSure Technologies (OSUR) Q4 Earnings Miss Estimates
OraSure (OSUR) delivered earnings and revenue surprises of -57.14% and 7.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies, Inc. Announces 2020 Full-Year and Fourth Quarter Financial Results and Provides COVID-19 Update
Full-Year 2020 Net Revenues of $172 Million Increased 11% Year-Over-Year, Driven by $50 Million in Sales of Oral Fluid Collection Devices for COVID-19 Molecular Testing
OraSure Technologies to Present at the Raymond James 42nd Annual Institutional Investors Conference
BETHLEHEM, Pa., Feb. 24, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and ana...
OraSure Technologies (OSUR) Reports Next Week: Wall Street Expects Earnings Growth
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.